Defining the clinical outcome status (COS) in sarcoidosis: Results of WASOG Task Force

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 28, Issue 1, 2011, Pages 56-64

  Baughman, Robert P ^a   Nagai, S ^b   Balter, M ^c   Costabel, U ^d   Drent, M ^e   Du Bois, R ^f   Grutters, J C ^g   Judson, M A ^h   Lambin, I ^d   Lower, E E ^a   Muller Quernheim, J ⁱ   Prasse, A ⁱ   Rizzato, G ^j   Rottoli, P ^k   Spagnolo, P ^l   Teirstein, A ^m  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^g ST ANTONIUS HOSPITAL   (Netherlands)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k UNIVERSITY OF SIENA   (Italy)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^m NONE

more..

Author keywords

Clinical outcome; Clinical phenotypes; Sarcoidosis

Indexed keywords

ARTICLE; CHRONIC GRANULOMATOUS DISEASE; GENOTYPE; LUNG SARCOIDOSIS; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; AGED; CHILD; CONGRESSES AS TOPIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; PHENOTYPE; PULMONARY MEDICINE; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; YOUNG ADULT;

EID: 79957942122     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (Sep): 149-73.
2. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111 (3): 623-31.
3. Prasse A, Katic C, Germann M, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008; 177 (3): 330-6.
4. Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung 1987; 165: 371-7. (Pubitemid 17165347)
5. Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121: 24-31. (Pubitemid 34114224)
6. Nagai S, Shigematsu M, Hamada K, et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 1999; 5 (5): 293-8.
7. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 208: 525-33. (Pubitemid 14245588)
8. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20 (3): 204-11. (Pubitemid 37351542)
9. Pietinalho A, Furuya K, Yamaguchi E, et al. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999; 13(Apr): 723-6. (Pubitemid 29234768)
10. Voorter CE, Drent M, Hoitsma E, et al. Association of HLA DQB1 0602 in sarcoidosis patients with small fiber neuropathy. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (2): 129-32. (Pubitemid 41020018)
11. Voorter CE, Drent M, van den Berg-Loonen EM. Severe pulmonary sarcoidosis is strongly associated with the haplotype HLA-DQB1*0602- DRB1*150101. Hum Immunol 2005; 66 (7): 826-35. (Pubitemid 41169773)
12. Grunewald J, Eklund A. Sex-specific manifestations of Lofgren's syndrome. Am J Respir Crit Care Med 2007; 175 (1): 40-4. (Pubitemid 46105307)
13. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287: 1301-7. (Pubitemid 34250485)
14. Baughman RP, du Bois RM, Lower EE. Sarcoidosis. Lancet 2003; 361: 1111-8.
15. Baughman RP, Shipley R, Desai S, et al. Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy: Comparison of Different Methods of Evaluation. Chest 2009; 136: 526-35.
16. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42 (8): 1031-9.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2): 228-47.
18. Suzuki C, Torkzad MR, Jacobsson H, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol 2010; 49 (4): 509-14.
19. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21 (13): 2574-82. (Pubitemid 46606340)
20. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75-86. (Pubitemid 29164274)
21. Mana J, Gomez VC, Montero A, et al. Lofgren's syndrome revisited: a study of 186 patients. Am J Med 1999; 107 (3): 240-5. (Pubitemid 29421590)
22. Baughman RP, Selroos O. Evidence-based approach to the treatment of sarcoidosis. In: Gibson PG, Abramson M, Wood-Baker R et al, editors. Evidence-based respiratory medicine. Maiden: Blackwell Publishing Ltd., 2005: 491-508.
23. Johns CJ, Michele TM. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins hospital. Medicine 1999; 78: 65-111.
24. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149 (4 Pt 1): 893-8.
25. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis 1998; 15: 52-8. (Pubitemid 28174897)
26. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006; 99 (5): 307-15.
27. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29 (3): 533-48.
28. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (7): 795-802. (Pubitemid 44511661)
29. Stagaki E, Mountford WK, Lackland DT, et al. The Treatment of Lupus Pernio: The Results of 116 Treatment Courses in 54 Patients. Chest 2008.
30. Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest 2003; 123: 406-12.
31. Grunewald J, Eklund A. Lofgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009; 179 (4): 307-12.
32. Wasfi YS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity. Chest 2006; 129 (5): 1234-45.
33. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31 (6): 1189-96.
34. Izumi T. Symposium: Population differences in clinical features and prognosis of sarcoidosis throughout the world. Sarcoidosis 1992; 9: S105-S118.
35. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57: 847-52.
36. Honeyboume D. Ethnic differences in the clinical features of sarcoidosis in South- East London. Br J Dis Chest 1980; 74: 63-9.
37. Lenner R, Schilero GJ, Padilla ML, et al. Sarcoidosis presenting in patients older than 50 years. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (2): 143-7. (Pubitemid 34685914)
38. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121: 32-39. (Pubitemid 34114225)